Kevin Kalinsky, MD, MS, discusses treatment options beyond chemotherapy in patients with high-risk breast cancer.
Kevin M. Kalinsky, MD, Columbia University Medical Center
Advertisement
Articles by Kevin M. Kalinsky, MD, Columbia University Medical Center
Future Directions for Treatment of TNBC
ByJoyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center,Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute,Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center,Kevin M. Kalinsky, MD, Columbia University Medical Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University
Phase 3 ASCENT Trial in mTNBC: Managing Adverse Events
ByJoyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center,Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute,Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center,Kevin M. Kalinsky, MD, Columbia University Medical Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University
Phase 3 ASCENT Trial in mTNBC
ByJoyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center,Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute,Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center,Kevin M. Kalinsky, MD, Columbia University Medical Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University
Sequencing Therapies for mTNBC
ByJoyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center,Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute,Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center,Kevin M. Kalinsky, MD, Columbia University Medical Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University
Standard of Care for BRCA+ mTNBC
ByJoyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center,Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute,Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center,Kevin M. Kalinsky, MD, Columbia University Medical Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University
Testing for PD-L1 Expression in mTNBC
ByJoyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center,Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute,Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center,Kevin M. Kalinsky, MD, Columbia University Medical Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University
KEYNOTE-355 Trial in mTNBC
ByJoyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center,Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute,Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center,Kevin M. Kalinsky, MD, Columbia University Medical Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University
Standard of Care for Metastatic TNBC
ByJoyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center,Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute,Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center,Kevin M. Kalinsky, MD, Columbia University Medical Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University
Current Trials for Treatment of Early Stage TNBC
ByJoyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center,Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute,Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center,Kevin M. Kalinsky, MD, Columbia University Medical Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University
Emerging Data on Biomarkers in ES TNBC
ByJoyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center,Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute,Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center,Kevin M. Kalinsky, MD, Columbia University Medical Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University
ICI-Based Therapy in TNBC: Immune-Related Adverse Events
ByJoyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center,Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute,Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center,Kevin M. Kalinsky, MD, Columbia University Medical Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University
Role of Immune Checkpoint Inhibitor-Based Therapy in ES TNBC
ByJoyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center,Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute,Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center,Kevin M. Kalinsky, MD, Columbia University Medical Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University
Early Stage TNBC: Phase 3 IMpassion031 Study
ByJoyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center,Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute,Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center,Kevin M. Kalinsky, MD, Columbia University Medical Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University
Key Trials in ICI-Based Therapy for Early Stage TNBC
ByJoyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center,Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute,Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center,Kevin M. Kalinsky, MD, Columbia University Medical Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University
Role of pCR in Early Stage TNBC Management
ByJoyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center,Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute,Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center,Kevin M. Kalinsky, MD, Columbia University Medical Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University
Standard of Care for Early-Stage TNBC
ByJoyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center,Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute,Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center,Kevin M. Kalinsky, MD, Columbia University Medical Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University
Advertisement
Latest Updated Articles
Testing for PD-L1 Expression in mTNBCPublished: October 23rd 2020 | Updated:
ICI-Based Therapy in TNBC: Immune-Related Adverse EventsPublished: October 23rd 2020 | Updated:
Sequencing Therapies for mTNBCPublished: October 23rd 2020 | Updated:
Role of Immune Checkpoint Inhibitor-Based Therapy in ES TNBCPublished: October 23rd 2020 | Updated:
Standard of Care for Metastatic TNBCPublished: October 23rd 2020 | Updated:
Future Directions for Treatment of TNBCPublished: October 23rd 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma
4
Ixazomib-Containing Combinations Signal Potential for More PI-Based Regimens in R/R Multiple Myeloma
5